A comparison of doubutamine and levosimendan on hepatic blood flow in patients with a low cardiac output state after cardiac surgery: a randomised controlled study SUMMArY liver dysfunction due to a low cardiac output state after cardiac surgery is associated with a poor prognosis, but whether one inotrope is superior to another in improving hepatic perfusion remains uncertain. this study compared the systemic and hepatic haemodynamic effects of levosimendan to dobutamine in patients with a low cardiac output state (cardiac index < 2.2 l/min/m2) after on-pump cardiac surgery. A total of 25 patients were randomised to receive either an intravenous bolus of levosimendan (12 µg/kg) over 15 minutes, followed by an infusion of 0.2 µg/kg/min for 24 hours, or an infusion of dobutamine 7.5 µg/kg/min for 24 hours and completed the study. the systemic and hepatic haemodynamics at 24 and 48 hours were all better after levosimendan than dobutamine (dobutamine group: cardiac index (l/min/m2)=2.51 [standard deviation ±0.29], 2.40±0.23; portal vein flow (ml/min): 614.0±124.7, 585.9±144.8; pulsatility index: 2.02±0,28, 2.98±0.27 versus the levosimendan group: cardiac index: 3.02± 0.27, 2.98± 0.30; portal vein flow: 723.0± 143.5, 702.9±117.8; pulsatility index: 1.71±0.26, 1.73±0.27). the improvement in portal vein blood flow at 48 hours was significantly better after levosimendan than dobutamine (41% vs. 11% increment from baseline, P<0.05). In addition, there was a significant reduction in hepatic artery resistance after levosimendan but not dobutamine (resistance index reduction 6.5% vs. 0%, P<0.05). In summary, levosimendan can be considered as a selective liver vasodilator and can improve hepatic blood flow through both the hepatic artery and portal venous system, whereas dobutamine can only improve the portal venous blood flow without vasodilating the hepatic artery.
Liver dysfunction following cardiopulmonary bypass (CPB) is associated with a poor prognosis and can be classified as mild, moderate or severe depending on its intensity. Mild hepatic dysfunction in the form of transient mild derangements in liver function tests in the postoperative period is very frequent and can occur in up to 47% of patients after cardiac surgery. Moderate hepatic dysfunction is defined by the presence of jaundice and a serum bilirubin concentration above 51.3 µmol/l and occurs in 3.2% of all patients after CPB 1, 2 . Risk factors for moderate hepatic dysfunction may include gender, New York Heart Association class status of advanced cardiac failure, type and duration of surgery, a low cardiac output state requiring inotropic agents and/or intra-aortic balloon pump, cardiac arrest, cardiac tamponade and massive blood transfusion. Patients with moderate hepatic dysfunction are associated with a prolonged period of mechanical ventilation, intensive care unit and hospital stays and have an increased risk of mortality (11.4%). Severe liver dysfunction after CPB is rare, related to coexisting cardiac failure, diabetes mellitus, arterial hypertension, postoperative low cardiac output state and female gender and is associated with a very high mortality rate 3 .
Mechanisms including preoperative cardiac failure, low splanchnic blood flow during CPB [1] [2] [3] [4] [5] and systemic inflammatory response 6 have been largely responsible for most patients who have hepatic dysfunction following CPB. Anaesthetic and surgical techniques may contribute to the pathogenesis of liver blood flow (lBF) disorders in surgical patients [7] [8] [9] and a low cardiac output state has been recognised to be an important element in the aetiology of liver insufficiency after cardiac surgery 3 . Beta-adrenergic agonists and phosphodiesterase III/IV inhibitors are commonly used for a low cardiac output state after cardiac surgery 10 , but in recent years levosimendan has been used as an alternative [11] [12] [13] [14] [15] [16] [17] . Whether the effects of levosimendan on the hepatic circulation are different from dobutamine in cardiac surgical patients remain uncertain.
We hypothesised that levosimendan may improve the hepatic perfusion better than dobutamine in patients with a low cardiac output state after on-pump cardiac surgery. In the study, we compared the liver haemodynamic parameters of randomised patients receiving either dobutamine or levosimendan for a low cardiac output syndrome after CPB. Specifically, we attempted to establish whether changes in lBF were due to a specific effect of the inotropes on the splanchnic circulation or just due to an improvement in the cardiac index (CI) of the patients.
MAterIAl AND MetHODS
this was a sub-study of a randomised controlled study previously published, and all patients described in this study were included in the prior publication 11 . Hepatic haemodynamics were studied in the first 32 patients of the 50 patients in that randomised controlled study 11 . this study was approved by the Clinical research ethics Committee of galicia in Spain (Approval no. 2005/268). Clinical trial registration for this study was not done as it was not required at the time of initiation of this study in Spain.
this was a prospective, randomised, open study involving patients who underwent on-pump cardiac surgery and had a low cardiac output state within the first four hours postoperatively. A low cardiac output was defined as a CI < 2.2 l/min/m2 without hypovolaemia (pulmonary capillary wedge pressure >15 mm Hg) despite adequate control of heart rate and absence of myocardial ischaemia or cardiac arrhythmias.
exclusion criteria included the existence of preoperative hepatic dysfunction-increased transaminase levels, increased bilirubin levels above 34.2 µmol/l, the prolongation of prothrombin time or international normalised ratio in the absence of use of anticoagulants, need for reoperation in the immediate postoperative period and the use of an intra-aortic balloon pump or any mechanical circulatory assistance device. Patients with one or more of the following clinical conditions were considered non compliant with the study inotropic protocol: dose reduction or drug removal for side effects, treatment continuing for over 24 hours for persistent low cardiac output parameters (CI <2.2 l/min/m2), requiring addition of other inotropic or vasoactive drugs and low blood pressure requiring the administration of vasoconstrictors to maintain a mean blood pressure >65 mmHg. the data of patients who did not complete the treatment protocol was not analysed in this study ( Figure 1 ).
Anaesthesia was induced using propofol, fentanyl and vecuroniun and maintained with fentanyl, vecuronium and sevoflurane in all cases. After anaesthetic induction, a Swan-ganz catheter was placed. All surgical procedures were carried out during CPB and all patients were extubated in the immediate postoperative period. Using numbered, sealed envelopes 32 patients with a low cardiac output state after surgery were allocated to two study groups. One group received dobutamine (Dobutamine Abbott, Madrid, Spain) (Dobutamine group, n=16) by continuous infusion at a dose of 7.5 µg/kg/min for 24 hours and another group received levosimendan (Simdax, espoo, Finland) (levosimendan group, n=16) with a starting dose of 12 µg/kg over 15 to 20 minutes followed by an infusion at a dose of 0.2 µg/kg/min for 24 hours.
Patients were monitored continuously during the study period and the following data were recorded: heart rate (beat.min-1), mean blood pressure (mmHg), central venous pressure (CVP; mmHg), mean pulmonary artery pressure (mmHg), pulmonary capillary wedge pressure (mmHg), cardiac output table 1 Clinical and demographic data of patients who completed the study and exclusion causes in each group.
Dobutamine group levosimendan group
Patients who completed the study 13 12 Patients excluded for persistent low cardiac index 2 0
Patients excluded for the use of vasoconstrictors 1 4
Age ( (l/min), mixed venous oxygen saturation (SvO 2 ; %) and hourly urine output. Immediately before starting the study inotropic treatment and at 24 and 48 hours afterwards, the following parameters were calculated: CI (l/min/m 2 ), systemic vascular resistances (dyn.sec.cm-5), pulmonary vascular resistance (dyn. sec.cm-5), stroke volume (ml), oxygen supply (DO2; ml/min) and consumption (VO 2 ; ml/min). the presence of any arrhythmia was recorded for all patients. Serum bilirubin, alkaline phosphatase (UI/l), the transaminases glutamic-oxalacetic (UI/l), glutamicpyruvic (UI/l) and gamma glutamyl transpeptidase (UI/l) were also assessed at baseline and at 24 and 48 hours after the initiation of the study drug. liver hemodynamics including the hepatic artery and portal vein blood flow were measured by ultrasound colour Doppler (Hewllett Packard Image Point HX, Hewlett Packard, U.S.A) with a multi-frequency probe of 2.5-7.5 MHz. Assessment was performed after extubation of the trachea and at 24 and 48 hours after beginning of study drug, by members of the Department of Hepatology who were blinded to study allocation of the patients. the technique was performed with the patient in the supine position during deep inspiration, and sampling volume was adjusted to two thirds of the diameter of the examined vessel [18] [19] [20] . the mean portal vein velocity (MPVV) was assessed and expressed as cm/seg. the portal vein flow (PVQ) was expressed as ml/min and it was calculated according to the formulae: PVQ=2/3*π*portal vein radius² and QPV= 2/3*Π*(portal radius)²*MPVV (MPVV in cm/min). A record of the hepatic artery was obtained at both intrahepatic and extrahepatic levels. Hepatic artery resistance index (rI) was calculated following the formula: rI=(ASV -ADV) / ASV, where ASV is hepatic artery systolic velocity (cm/seg) and ADV is hepatic artery diastolic velocity (cm/seg). Hepatic artery pulsatility index (PI) was calculated according to the formula: PI=(ASV-ADV)/AMV, where AMV is the hepatic artery mean velocity (cm/ seg). the liver vascular index 21 was calculated as the ratio of mean portal vein velocity to PI.
Statistical analysis
A sample size of 11 patients per group was needed to achieve a ß error <20% to detect an increase in CI of more than 20% from the baseline at 24 hours after the initiation of the study drug, assuming an-ß error of 5% as acceptable. the statistical study was conducted by SPSS version 20.0 for Windows (SPSS Inc., Chicago, Il, US) and r statistical software (version 3.0.1, r Development Core team, 2013, Vienna, Austria). Numerical results are given as mean value ± standard deviation. the data distributions were initially calculated using the Shapiro-Wilk test for normality and the Levene's test for homoscedasticity. the continuous variables were compared between the two groups over time using a two-way analysis of variance. Data that was not assumed to be either normal or homoscedastic was analysed by means of the Kruskal-Wallis test. A P-value <0.05 was considered as statistically significant for the two-way analysis of variance. In the case of Kruskal-Wallis, three tests were performed for each dependent variable: changes over time for each group and the difference between groups and where Bonferroni correction was applied, resulting in a P-value threshold of 0.005/3=0.0167. the data on the patients who did not complete the treatment protocol were not analysed in the comparative statistical study.
reSUltS table 1 shows both clinical and demographic data of the patients who completed the study and the reasons for exclusion in each study group.
three patients in the dobutamine group were excluded from the study within the first four hours due to persistent signs of low cardiac output, either requiring the dobutamine dose to be increased, concomitant treatment with another agent (two patients), or low blood pressure requiring vasoconstrictors (one patient). Four patients in the levosimendan group were excluded within the first four hours of treatment due to low blood pressure, requiring levosimendan reduction or withdrawal and the subsequent administration of vasoconstrictors and other positive inotropic drugs.
the systemic and hepatic haemodynamics of the patients are shown in tables 2 and 3, respectively. No patient had significant postoperative liver complications. One death in each group was registered in the late postoperative period (>15 days) due to respiratory complications. Figure 2 shows the main global changes in the haemodynamic parameters between the dobutamine and levosimendan groups. Figures 3, 4 and 5 represent the changes over time and their differences between the two groups in PVQ, rI and in PI. Data distributions for rI and PI, even after appropriate transformations, remained unsuitable for parametric analysis using a two-way analysis of variance. \ \DISCUSSION the main limitations of this study were the small sample size and the significant proportion of patients who failed to complete the study protocol. Although the doses of levosimendan and dobutamine used in this study were within the recommendations of the european Society of Cardiology 22 , four patients in the levosimendan group and one patient in the dobutamine group developed hypotension requiring treatment with α-mimetic drugs. In the daily postoperative care of cardiac surgical patients, hypotension after the initiation of inodilators is not rare and will usually respond to a reduction in the dose of the drug and/or addition of an α-mimetic 13, 23 . After excluding the patients who required vasopressors, our study showed that levosimendan was associated with a higher CI increment than dobutamine (see table 2 and Figure 2 ) in patients with a low cardiac output state, consistent with the findings from other studies [12] [13] [14] [15] [16] [17] .
In our study, the primary objective was the effects of levosimendan on the hepatic circulation. the measurement of lBF is complicated due to the double circulation model. the hepatic artery flow contributes 25% to 35% of the lBF and the portal vein contributes 65% to 75% of the lBF. In total, lBF accounts for 25% to 30% of the cardiac ouput 21 . the three determinants of lBF are intestinal vascular resistances that determine the intestinal flow and portal vein flow, the arteriolar resistances in the territory of the hepatic artery and the intrahepatic resistances to portal flow that are less important than mesenteric resistances 24 . Furthermore, there is a buffer mechanism in the hepatic arterial circulation that forms a feedback between the portal flow and vascular resistances in the hepatic artery so that when PVQ increases the resistance of the hepatic artery also increases 21, [24] [25] [26] [27] . On the other side, the arterial liver circulation lacks self-regulation which means that the relationship between perfusion pressure of the liver and lBF flow is linear. the 'gold standard' for the calculation of liver blood flow is the continuous infusion of indocyanine green through the hepatic vein. this technique is complex and very invasive and hence, not widely used in the clinical setting. For these reasons, most research groups, including our group, prefer to use non-invasive techniques of echo Doppler ultrasound of the portal vein and of the hepatic artery to measure hepatic blood flow [18] [19] [20] .
In our study, the mean portal vein velocity was significantly higher in both groups at 24 hours compared to the baseline (table 3) . However, in the levosimendan group this increase was more substantial. PVQ had a similar behaviour. With regard to the PI and rI-used to assess liver flow through the hepatic artery-there was a clear reduction in both groups which indicated vasodilation, although it was also more substantial in the levosimendan group (table 3, Figures 4 and 5) . therefore, there was a more significant vasodilation of the arterial system of the hepatic artery after the use of levosimendan compared to dobutamine.
With these data, it can be stated that levosimendan acts as a vasodilator in the liver circulation and that this effect is stronger than that seen with dobutamine. the PVQ increase observed in the levosimendan group can be explained by three mechanismsthe CI increase raises perfusion, the improvement of the right ventricle function with central venous pressure reduction which reduces the congestion of the abdominal organs and increases flow through the portal vein, and direct liver vasodilatation, due to the effect of levosimendan on adenosine triphosphate dependent potassium channels.
However, there are also other mechanisms that can affect liver flow in patients undergoing major general and cardiac surgery 1, 4, 5 including the effect of halogenated anaesthetics 8 , assisted ventilation 1,28 and short-term haemodynamic fluctuations that reduce lBF. the effect of other drugs on lBF with a potent systemic vasodilator capacity is variable. Prostaglandin e1 29 , fenoldopam and dopexamine 30 do not modify lBF, but adenosine induces vasodilatation of the hepatic artery in patients with cirrhosis and increases the lBF. the mechanism of action of levosimendan is peculiar. Although levosimendan can reduce mean blood pressure, it also reduces the central venous pressure and hence the reduction in liver perfusion pressure is not substantial. this was also observed in an experimental model of septic shock treated with levosimendan 31 . Within the hepatic circulation, arterial and venous vasodilation occurs with levosimendan. the arterial dilation explains the reduction in rI and PI we observed and the venous dilation explains the improvement in PVQ. Such observations were also observed in an animal model of sepsis 31 .
the important question to answer is whether any improvement in PVQ after levosimendan is due to vasodilatation within the hepatic circulation, or nonspecific and only related to an improvement in cardiac output. Our results were conclusive in this regard. the percentage of PVQ increase (PVQ at 24 hours was 46% above baseline) was virtually identical to the percentage of CI increase (CI at 24 hours was 38% above baseline), i.e., it appeared to have no specificity for hepatic portal vein vasodilation occurring in the levosimendan group and in the dobutamine group. the PVQ increase was higher in the levosimendan group, simply because the increase in CI was also higher. However, within this mechanism it was surprising that the non-specific vasodilatation of the portal system -referred to as the increase in PVQ or ΔPVQ, clearly demonstrated in the levosimendan group and also present in the dobutamine groupshowed no vasoconstriction of the hepatic artery system.
the relationship between the PVQ and vascular resistances in the arterial perfusion through the hepatic artery has been known for some time. this mechanism, known as the hepatic arterial buffer response 32 , did not appear to act in either of the two groups analysed, given that both groups showed an increase in PVQ. In the dobutamine group neither PI nor rI changed and in the levosimendan group, both rI and PI decreased on a statistically significant basis.
CONClUSION
In conclusion, the use of levosimendan increases the portal vein flow in a percentage similar to the improvement in cardiac index and also reduces arterial resistance in the hepatic artery. As such, levosimendan can be considered as a selective liver vasodilator and can improve hepatic blood flow through both the hepatic artery and portal venous system; whereas dobutamine can only improve portal venous blood flow without vasodilating the hepatic artery.
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